Specialty & Generic Drug Manufacturers industry stocks
84 companies in the Specialty & Generic Drug Manufacturers industry. 38 have a published intrinsic value and 16 trade at least 20% below it.
The median company in Specialty & Generic Drug Manufacturers with a published value trades 11% above our estimate of intrinsic value.
Values as of the 22 Sept 2026 close.
Most undervalued stocks in Specialty & Generic Drug Manufacturers
- Biocryst Pharmaceuticals Inc (BCRX): undervalued, +77% margin of safety
- Collegium Pharmaceutical Inc (COLL): undervalued, +76% margin of safety
- Organogenesis Holdings Inc (ORGO): undervalued, +72% margin of safety
- Ironwood Pharmaceuticals Inc (IRWD): undervalued, +65% margin of safety
- Tilray Brands Inc (TLRY): undervalued, +63% margin of safety
- ANI Pharmaceuticals Inc (ANIP): undervalued, +61% margin of safety
- Amphastar Pharmaceuticals Inc (AMPH): undervalued, +52% margin of safety
- Indivior Pharmaceuticals Inc (INDV): undervalued, +48% margin of safety
- Phibro Animal Health Corp (PAHC): undervalued, +47% margin of safety
- Pacira BioSciences Inc (PCRX): undervalued, +45% margin of safety
Liquid names only: at least $1M traded a day and $50M of market value.
Largest companies in Specialty & Generic Drug Manufacturers
- Takeda Pharmaceutical Co ADR (TAK): overvalued, -86% margin of safety
- Teva- Pharmaceutical Industries Ltd (TEVA): overvalued, -92% margin of safety
- Haleon plc ADR (HLN): slightly overvalued, -14% margin of safety
- Zoetis Inc (ZTS): undervalued, +36% margin of safety
- United Therapeutics Corp (UTHR): undervalued, +35% margin of safety
- Viatris Inc (VTRS): not valued
- Neurocrine Biosciences Inc (NBIX): undervalued, +29% margin of safety
- Elanco Animal Health Inc (ELAN): overvalued, -364% margin of safety
- Dr. Reddy's Laboratories Ltd ADR (RDY): overvalued, -53% margin of safety
- Alkermes plc (ALKS): overvalued, -392% margin of safety
- Hims & Hers Health Inc (HIMS): overvalued, -45% margin of safety
- Lantheus Holdings Inc (LNTH): slightly undervalued, +11% margin of safety
- Amneal Pharmaceuticals Inc (AMRX): overvalued, -53% margin of safety
- Liquidia Corp (LQDA): overvalued, -45% margin of safety
- Kiniksa Pharmaceuticals International Plc (KNSA): not valued
- Indivior Pharmaceuticals Inc (INDV): undervalued, +48% margin of safety
- Amylyx Pharmaceuticals Inc (AMLX): no published value
- Regencell Bioscience Holdings Ltd (RGC): no published value
- Supernus Pharmaceuticals Inc (SUPN): overvalued, -48% margin of safety
- HUTCHMED (China) Limited ADR (HCM): not valued
- Trulieve Cannabis Corp (TRLV): slightly overvalued, -10% margin of safety
- Alvotech (ALVO): not valued
- Prestige Consumer Healthcare Inc (PBH): undervalued, +29% margin of safety
- Biocryst Pharmaceuticals Inc (BCRX): undervalued, +77% margin of safety
- Bausch Health Companies Inc (BHC): no reliable verdict
- Perrigo Company plc (PRGO): not valued
- ANI Pharmaceuticals Inc (ANIP): undervalued, +61% margin of safety
- Eton Pharmaceuticals Inc (ETON): overvalued, -597% margin of safety
- Xeris Biopharma Holdings Inc (XERS): overvalued, -307% margin of safety
- Phibro Animal Health Corp (PAHC): undervalued, +47% margin of safety
- Harrow Inc (HROW): overvalued, -367% margin of safety
- Cronos Group Inc (CRON): slightly overvalued, -11% margin of safety
- Amphastar Pharmaceuticals Inc (AMPH): undervalued, +52% margin of safety
- Pacira BioSciences Inc (PCRX): undervalued, +45% margin of safety
- Ironwood Pharmaceuticals Inc (IRWD): undervalued, +65% margin of safety
- Collegium Pharmaceutical Inc (COLL): undervalued, +76% margin of safety
- Aquestive Therapeutics Inc (AQST): overvalued, -402% margin of safety
- Glass House Brands Inc (GLAS): not valued
- Tilray Brands Inc (TLRY): undervalued, +63% margin of safety
- Evotec SE ADR (EVO): not valued
- Evolus Inc (EOLS): overvalued, -76% margin of safety
- Kamada Ltd (KMDA): overvalued, -21% margin of safety
- Alpha Teknova Inc (TKNO): overvalued, -1228% margin of safety
- Canopy Growth Corp (CGC): not valued
- BioAge Labs Inc (BIOA): not valued
- Emergent Biosolutions Inc (EBS): no reliable verdict
- Anika Therapeutics Inc (ANIK): not valued
- Aurora Cannabis Inc (ACB): not valued
- Akebia Therapeutics Inc (AKBA): not valued
- SIGA Technologies Inc (SIGA): not valued
- Cardiol Therapeutics Inc (CRDL): no published value
- Journey Medical Corp (DERM): overvalued, -79% margin of safety
- Organogenesis Holdings Inc (ORGO): undervalued, +72% margin of safety
- Lifecore Biomedical Inc (LFCR): no published value
- Adc Therapeutics SA (ADCT): not valued
- Organigram Global Inc (OGI): undervalued, +42% margin of safety
- Cumberland Pharmaceuticals Inc (CPIX): not valued
- BGM Group Ltd (BGM): not valued
- Citius Oncology Inc (CTOR): not valued
- Intercure Ltd (INCR): slightly overvalued, -11% margin of safety
- Talphera Inc (TLPH): no published value
- Scynexis Inc (SCYX): not valued
- Incannex Healthcare Inc (IXHL): no published value
- Zhengye Biotechnology Holding Ltd (ZYBT): not valued
- Rockwell Medical Inc (RMTI): not valued
- China Pharma Holdings Inc (CPHI): not valued
- Optimi Health Corp (OPTH): not valued
- TherapeuticsMD Inc (TXMD): not valued
- Aytu BioPharma Inc (AYTU): not valued
- Universe Pharmaceuticals INC (UPC): not valued
- Biofrontera Inc (BFRI): undervalued, +79% margin of safety
- InMed Pharmaceuticals Inc (INM): not valued
- Gelteq Ltd (GELS): not valued
- Sonoma Pharmaceuticals Inc (SNOA): no reliable verdict
- cbdMD Inc (YCBD): not valued
- Sunshine Biopharma Inc (SBFM): not valued
- Redhill Biopharma Ltd ADR (RDHL): no published value
- China SXT Pharmaceuticals Inc (SXTC): not valued
- PRF Technologies Ltd (PRFX): not valued
- Apimeds Pharmaceuticals US Inc (APUS): no published value
- IM Cannabis Corp (IMCC): not valued
- Akanda Corp (AKAN): not valued
- Shuttle Pharmaceuticals Holdings Inc (SHPH): no published value
- Caring Brands Inc (CABR): no published value
Other Healthcare industries
All industries